Clinical Trial Search

Primary: Relative Risk of Medically Attended Events Between 30-day Risk Window and 30-day Self-control Window: Pre-Dose 1 Inpatient — 0.98; 0.46; 0.98; 0.30 ratio — p=0.98

Primary: Serum Hemagglutination Inhibition (HI) Antibody Titers Against Each of the Four Vaccine Strains After 1 Dose of Fluarix Quadrivalent Vaccine — 43.1; 14.5; 445.6; 45.8…

Primary: Disease Activity Score Based on 28-Joint Count (DAS28) — 6.03; 4.01 units on a scale — p=<0.0001

Primary: Mean Ratio Actual Fraction of Cells Remaining (FCRa; as Measured by Post-Procedure % HbS) to the Predicted Fraction of Cells Remaining (FCRp; as Predicted by the Spectra…

Primary: Percentage of Participants With Progression-free Survival (PFS) — 35.3 percentage of participants

Primary: Progression Free Survival — 7.8 months

Primary: Percentage of Participants With Treated Biopsy Proven Acute Rejection (BPAR) According to Banff Criteria up to 12 Months Post-Transplant — 8.0; 8.2 percentage of…

Primary: Number of Participants Who Had Treatment-Emergent Adverse Events (TEAEs); Data Analysis Cut-Off: September 27, 2013 — 76; 68 participants

Primary: Behavioral & Mood Measure: Profile of Mood States (POMS) — 57.7; 55.5; -4.5; -0.1 units on a scale

Primary: Pain Intensity — 1.66; 1.60 Points on numerical rating scale

Primary: Final Clinical Cure Rate — 101; 102; 73 participants — p=0.0001

Primary: Mean Linear Wear Rate at 5 Years — 0.016 mm/year

Primary: Mean Intrapatient Change in Ethmoid Lund-MacKay CT Score (Ethmoid Score Only) at 10 Weeks Post-procedure Compared to Baseline. — -1.91 scores on a scale

Primary: Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Week 10/13 - Last Observation Carried Forward…

Primary: Change in Tibia Trabecular Volumetric Bone Mineral Density (BMD) Z-score at 12 Months — 0.15; 0.23 Z-score — p=0.38